Contribute Try STAT+ Today

As pharmacy benefit managers undergo increasing scrutiny, two lawmakers have asked the Health and Human Services inspector general to investigate so-called spread pricing practices by these pharmaceutical middlemen as part of a larger inquiry into rising drug costs.

In an April 8 letter released on Wednesday night, the heads of the Senate Finance Committee pointed to instances where PBMs have purportedly used this practice to make millions of dollars in excess profits at the expense of state Medicaid programs. Spread pricing is a crucial but little-known part of the opaque pharmaceutical pricing system and refers to fees PBMs pay pharmacies and bill back to Medicaid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Well Ed, I think these legislators are finally getting what Independent pharmacies have been dealing with for years.
    It’s really so easy to see yet no one saw it except independent pharmacists. How the folks at PCMA can sleep at night is beyond me. D.O.J needs to step in and do something about what PBM’s have grown into. You have one corporation that won’t show anyone their books or their pricing schedules.
    PBM’s have multiple MAC (Maximum Allowable Cost) price lists. There is no standardization in the industry as to the criteria for the inclusion of drugs on MAC lists or for the methodology as to how the PBM will determine the
    maximum price or how it’s changed or updated. PBMs have free reign on developing these methodologies and in
    turn, the ultimate price. The PBM’s client is left entirely in the dark. PBM’s pay pharmacies the low reimbursement
    MAC list and collect the high MAC price list. But no one can see this . This is the reason for lack of transparency !

Comments are closed.